JP6737813B2 - 懸濁細胞の小スケール培養 - Google Patents
懸濁細胞の小スケール培養 Download PDFInfo
- Publication number
- JP6737813B2 JP6737813B2 JP2017560971A JP2017560971A JP6737813B2 JP 6737813 B2 JP6737813 B2 JP 6737813B2 JP 2017560971 A JP2017560971 A JP 2017560971A JP 2017560971 A JP2017560971 A JP 2017560971A JP 6737813 B2 JP6737813 B2 JP 6737813B2
- Authority
- JP
- Japan
- Prior art keywords
- culture
- cells
- cell
- perfusion
- small scale
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000725 suspension Substances 0.000 title claims description 31
- 210000004027 cell Anatomy 0.000 claims description 257
- 238000004113 cell culture Methods 0.000 claims description 174
- 230000010412 perfusion Effects 0.000 claims description 111
- 239000001963 growth medium Substances 0.000 claims description 97
- 238000000034 method Methods 0.000 claims description 75
- 238000013019 agitation Methods 0.000 claims description 37
- 238000012258 culturing Methods 0.000 claims description 27
- 238000004062 sedimentation Methods 0.000 claims description 27
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 26
- 239000001301 oxygen Substances 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 238000001556 precipitation Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 235000015097 nutrients Nutrition 0.000 claims description 16
- 238000012216 screening Methods 0.000 claims description 15
- 102000003886 Glycoproteins Human genes 0.000 claims description 11
- 108090000288 Glycoproteins Proteins 0.000 claims description 11
- 239000007789 gas Substances 0.000 claims description 11
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 10
- 230000000740 bleeding effect Effects 0.000 claims description 9
- 208000025113 myeloid leukemia Diseases 0.000 claims description 9
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 8
- 210000000601 blood cell Anatomy 0.000 claims description 6
- 230000003833 cell viability Effects 0.000 claims description 6
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 230000013595 glycosylation Effects 0.000 description 20
- 238000006206 glycosylation reaction Methods 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000035899 viability Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 238000003306 harvesting Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 230000033581 fucosylation Effects 0.000 description 5
- 150000004676 glycans Chemical group 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 238000012007 large scale cell culture Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 3
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 3
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229940126587 biotherapeutics Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 238000012368 scale-down model Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU92727 | 2015-05-29 | ||
| LU92727 | 2015-05-29 | ||
| EP16151811 | 2016-01-19 | ||
| EP16151811.3 | 2016-01-19 | ||
| PCT/EP2016/061763 WO2016193083A1 (en) | 2015-05-29 | 2016-05-25 | Small scale cultivation method for suspension cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516077A JP2018516077A (ja) | 2018-06-21 |
| JP2018516077A5 JP2018516077A5 (enExample) | 2019-06-13 |
| JP6737813B2 true JP6737813B2 (ja) | 2020-08-12 |
Family
ID=56108615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560971A Active JP6737813B2 (ja) | 2015-05-29 | 2016-05-25 | 懸濁細胞の小スケール培養 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180135091A1 (enExample) |
| EP (1) | EP3303557B1 (enExample) |
| JP (1) | JP6737813B2 (enExample) |
| KR (1) | KR20180010200A (enExample) |
| CN (1) | CN108138128A (enExample) |
| AU (1) | AU2016272566A1 (enExample) |
| BR (1) | BR112017023624A2 (enExample) |
| CA (1) | CA2985435A1 (enExample) |
| RU (1) | RU2730656C2 (enExample) |
| WO (1) | WO2016193083A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016272566A1 (en) | 2015-05-29 | 2017-11-23 | Glycotope Gmbh | Small scale cultivation method for suspension cells |
| EP3472338B1 (en) | 2016-06-20 | 2024-05-22 | Octapharma AG | Means and methods for modifying multiple alleles |
| EP3522128B1 (en) * | 2016-09-29 | 2021-01-27 | Coaido Inc. | Disaster emergency system for simultaneously calling telephones in region |
| JP7317466B2 (ja) * | 2017-12-12 | 2023-07-31 | 株式会社日立製作所 | 細胞株及び培養条件のスクリーニング方法、及びその装置 |
| CN111139216B (zh) * | 2018-11-01 | 2024-09-03 | 上海药明生物技术有限公司 | 高通量、自动化的细胞连续培养方法及其应用 |
| US20220177818A1 (en) * | 2019-04-01 | 2022-06-09 | The Automation Partnership (Cambridge ) Ltd. | Operation process for a cell cultivation system |
| CN113795885A (zh) * | 2019-05-08 | 2021-12-14 | 齐默尔根公司 | 缩小参数以设计在小规模下的微生物的实验及板模型以改进对在更大规模下的性能的预测 |
| BR112022000061A2 (pt) * | 2019-07-01 | 2022-05-24 | Ology Bioservices Inc | Método para o cultivo de células aderentes em um bioreator multiparalelo |
| CN118064651B (zh) * | 2024-03-11 | 2025-03-11 | 上海迈邦生物科技有限公司 | 一种细胞灌流培养体系维持稳态的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5320963A (en) * | 1992-11-25 | 1994-06-14 | National Research Council Of Canada | Bioreactor for the perfusion culture of cells |
| JP2997771B2 (ja) * | 1998-06-29 | 2000-01-11 | 金沢大学長 | 細胞の懸濁培養方法 |
| US20040185534A1 (en) * | 2000-10-02 | 2004-09-23 | Knudsen Ida Molgaard | Industrial-scale serum-free production of recombinant proteins in mammalian cells |
| US20040185535A1 (en) | 2003-03-21 | 2004-09-23 | Giles Wilson | Industrial-scale serum-free production of recombinant FVII in mammalian cells |
| WO2007071072A1 (en) | 2005-12-22 | 2007-06-28 | Corporation De L'ecole Polytechnique De Montreal | High-rate perfusion bioreactor |
| CN101490239A (zh) * | 2006-07-14 | 2009-07-22 | 帝斯曼知识产权资产管理有限公司 | 改进的细胞培养方法 |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| NO2501822T3 (enExample) * | 2009-11-17 | 2018-01-13 | ||
| DK2655600T3 (en) * | 2010-12-21 | 2017-05-15 | Glycotope Gmbh | METHODS FOR CULTIVATING HUMAN MYELOID LEUKEMIC CELLS AND CELLS DERIVED FROM THERE |
| EP2599651A1 (de) | 2011-12-01 | 2013-06-05 | Magna E-Car Systems GmbH & Co OG | Heiz-/Kühlsystem für eine Batterie eines Kraftfahrzeugs sowie Betriebsverfahren hierfür |
| CN102690781B (zh) * | 2012-04-28 | 2014-04-30 | 苏州金盟生物技术有限公司 | 一种灌流式细胞培养的培养基更换方法 |
| CN104195187B (zh) | 2014-08-01 | 2018-02-16 | 润科生物工程（福建）有限公司 | 沉降‑逆灌流‑放流偶联制备富含dha油脂的方法及其专用细胞沉降槽 |
| AU2016272566A1 (en) | 2015-05-29 | 2017-11-23 | Glycotope Gmbh | Small scale cultivation method for suspension cells |
-
2016
- 2016-05-25 AU AU2016272566A patent/AU2016272566A1/en not_active Abandoned
- 2016-05-25 JP JP2017560971A patent/JP6737813B2/ja active Active
- 2016-05-25 CA CA2985435A patent/CA2985435A1/en not_active Abandoned
- 2016-05-25 EP EP16727348.1A patent/EP3303557B1/en not_active Revoked
- 2016-05-25 BR BR112017023624A patent/BR112017023624A2/pt not_active Application Discontinuation
- 2016-05-25 RU RU2017140920A patent/RU2730656C2/ru active
- 2016-05-25 US US15/574,250 patent/US20180135091A1/en not_active Abandoned
- 2016-05-25 CN CN201680030077.0A patent/CN108138128A/zh active Pending
- 2016-05-25 WO PCT/EP2016/061763 patent/WO2016193083A1/en not_active Ceased
- 2016-05-25 KR KR1020177034153A patent/KR20180010200A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017140920A (ru) | 2019-07-01 |
| RU2017140920A3 (enExample) | 2019-07-17 |
| CA2985435A1 (en) | 2016-12-08 |
| EP3303557A1 (en) | 2018-04-11 |
| US20180135091A1 (en) | 2018-05-17 |
| AU2016272566A1 (en) | 2017-11-23 |
| RU2730656C2 (ru) | 2020-08-24 |
| EP3303557B1 (en) | 2021-05-05 |
| KR20180010200A (ko) | 2018-01-30 |
| CN108138128A (zh) | 2018-06-08 |
| JP2018516077A (ja) | 2018-06-21 |
| WO2016193083A1 (en) | 2016-12-08 |
| BR112017023624A2 (pt) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6737813B2 (ja) | 懸濁細胞の小スケール培養 | |
| AU2022224699B2 (en) | Methods For Harvesting Mammalian Cell Cultures | |
| Amanullah et al. | Novel micro‐bioreactor high throughput technology for cell culture process development: Reproducibility and scalability assessment of fed‐batch CHO cultures | |
| Eaker et al. | Bioreactors for cell therapies: current status and future advances | |
| Rodrigues et al. | Technological progresses in monoclonal antibody production systems | |
| Janoschek et al. | A protocol to transfer a fed‐batch platform process into semi‐perfusion mode: the benefit of automated small‐scale bioreactors compared to shake flasks as scale‐down model | |
| JP6915992B2 (ja) | 灌流培養方法およびその使用 | |
| Kreye et al. | A novel scale‐down mimic of perfusion cell culture using sedimentation in an automated microbioreactor (SAM) | |
| JP6096123B2 (ja) | ヒト骨髄性白血病細胞およびそれに由来する細胞を培養するための方法 | |
| Mayrhofer et al. | Shake tube perfusion cell cultures are suitable tools for the prediction of limiting substrate, CSPR, bleeding strategy, growth and productivity behavior | |
| CN110106139B (zh) | 一种基于Tubespin生物反应器的缩小模型的细胞灌流培养方法 | |
| Harigae et al. | Kinetic study on HBs-MAb production in continuous cultivation | |
| Yang | Mammalian fed‐batch cell culture for biopharmaceuticals | |
| Mehra et al. | Advanced bioprocess engineering: fed‐batch and perfusion processes | |
| Wolf | Development and optimization of mammalian cell perfusion cultures for continuous biomanufacturing | |
| JP2009514532A (ja) | 哺乳動物細胞を適応させるための方法 | |
| JP2012504394A (ja) | 小規模振盪フラスコ培養 | |
| Rathore et al. | In Focus: Continuous bioprocessing. | |
| CN210340843U (zh) | 贴壁细胞微载体培养装置 | |
| Bielser | Development of perfusion cell culture processes for the manufacturing of therapeutic recombinant proteins | |
| Lin et al. | Development and Application of an Animalcomponent Free Single-cell Cloning Medium for Chinese Hamster Ovary Cell Lines | |
| Ravindran et al. | Mammalian Cell Culture | |
| Metze | Scalability of single-use biopharmaceutical manufacturing processes using process analytical technology (PAT) tools | |
| Kunert | Experimental design and small-scale model for high-performing perfusion media and processes scalable to 50 L bioreactors | |
| Paul et al. | Maintaining product titer while replacing undefined components in a CHO culture system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190509 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190509 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200521 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200702 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200716 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6737813 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |